keyword
MENU ▼
Read by QxMD icon Read
search

neda AND "multiple sclerosis"

keyword
https://www.readbyqxmd.com/read/30539030/safety-and-efficacy-of-rituximab-in-multiple-sclerosis-a-retrospective-observational-study
#1
Bassem I Yamout, Nabil K El-Ayoubi, Johny Nicolas, Yehya El Kouzi, Samia J Khoury, Maya M Zeineddine
Objective: To evaluate the efficacy and safety of rituximab in multiple sclerosis in a clinical practice setting. Methods: Clinical data for all adult patients with multiple sclerosis (MS) treated with off-label rituximab at a single MS center in Lebanon between March 2008 and April 2017 were retrospectively collected from medical charts. The main efficacy outcomes assessed were annualized relapse rate (ARR) and proportion of patients free from relapses, disability progression, or magnetic resonance imaging (MRI) activity...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/30513578/multiple-sclerosis-a-global-concern-with-multiple-challenges-in-an-era-of-advanced-therapeutic-complex-molecules-and-biological-medicines
#2
Victor M Rivera
Multiple sclerosis (MS) has become a common neurological disorder involving populations previously considered to be infrequently affected. Genetic dissemination from high- to low-risk groups is a determining influence interacting with environmental and epigenetic factors, mostly unidentified. Disease modifying therapies (DMT) are effective in treating relapsing MS in variable degrees; one agent is approved for primary progressive disease, and several are in development. In the era of high-efficacy medications, complex molecules, and monoclonal antibodies (MAB), including anti-VLA4 (natalizumab), anti-CD52 (alemtuzumab), and anti-CD20 (ocrelizumab), obtaining NEDA (no evidence of disease activity) becomes an elusive accomplishment in areas of the world where access to MS therapies and care are generally limited...
November 30, 2018: Biomedicines
https://www.readbyqxmd.com/read/30488803/molecular-mechanisms-of-curcumin-in-neuroinflammatory-disorders-a-mini-review-of-current-evidences
#3
Mahsa Hatami, Mina Abdolahi, Neda Soveyd, Mahmoud Djalali, Mansoureh Togha, Niyaz Mohammadzadeh Honarvar
OBJECTIVE: Neuroinflammatory disease is a general term used to denote the progressive loss of neuronal function or structure. Many neuroinflammatory diseases, including Alzheimer's, Parkinson's, and multiple sclerosis (MS), occur due to neuroinflammation. Neuroinflammation increases nuclear factor-κB (NF-κB) levels, cyclooxygenase-2 enzymes and inducible nitric oxide synthase, resulting in the release of inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α)...
November 28, 2018: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/30443887/immune-reconstitution-therapy-irt-in-multiple-sclerosis-the-rationale
#4
REVIEW
Dimitrios Karussis, Panayiota Petrou
Immunotherapy of multiple sclerosis (MS) and other neuroimmune diseases is rapidly evolving. For the past 25 years, there has been an accelerating inclusion of new immunomodulating drugs. Based on their molecular construction and their basic mechanism of action, immunotherapeutic agents belong to the following categories: (1) cytotoxic drugs, (2) synthetic immunomodulators, (3) monoclonal antibodies, (4) vaccines (T cell vaccines, antigen vaccines), (5) oral tolerizing agents, (6) modalities that act as indirect immunosuppressants (plasmapheresis, intravenous immunoglobulins [IVIG]), and (7) cellular therapies...
November 16, 2018: Immunologic Research
https://www.readbyqxmd.com/read/30401571/brain-volume-loss-and-no-evidence-of-disease-activity-over-3-years-in-multiple-sclerosis-patients-under-interferon-beta-1a-subcutaneous-treatment
#5
J I Rojas, F Sanchez, F Caro, J Miguez, L Patrucco, J Funes, E Cristiano
The objective of our study was to evaluate the relationship of percentage of annualized brain volume loss (aBVL) and no evidence of disease activity (NEDA) in multiple sclerosis (MS) patients under interferon beta 1-a subcutaneous treatment (IFN-beta) during 3 years of follow up. Relapsing remitting MS (RRMS) patients, with less than three years from disease onset, expanded disability status scale (EDSS) ≤3 and in which IFN beta 1-a 44 mcg was indicated, were included. Demographic, clinical and structural parameters from the magnetic resonance (MR) during the 3 years of follow up were analyzed and compared between patients with and without NEDA (defined as the absence of: (a) three-month confirmed disability progression defined as an increase in EDSS score of 1...
November 3, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/30386435/neda-3-status-including-cortical-lesions-in-the-comparative-evaluation-of-natalizumab-versus-fingolimod-efficacy-in-multiple-sclerosis
#6
Marco Puthenparampil, Chiara Cazzola, Sofia Zywicki, Lisa Federle, Erica Stropparo, Mariagiulia Anglani, Francesca Rinaldi, Paola Perini, Paolo Gallo
Background: Cortical lesions (CLs) are typical of multiple sclerosis (MS) and have been recently incorporated in MS diagnostic criteria. Thus, the 'no evidence of disease activity' (NEDA) definition should now include CLs. The aim of this study was to evaluate the NEDA3 + CL status in natalizumab- or fingolimod-treated relapsing remitting MS (RMS) patients. Methods: Natalizumab- or fingolimod-treated RMS patients were enrolled in a 2-year longitudinal study based on clinical and magnetic resonance imaging (MRI) evaluations performed respectively biannually and annually...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/30384198/no-evidence-of-disease-activity-status-over-3-years-in-a-real-world-cohort-of-relapsing-remitting-ms-patients-in-germany
#7
Konstantin Huhn, Daniela Senger, Kathrin S Utz, Manuel Schmidt, Kilian Fröhlich, Anne Waschbisch, Frank Seifert, Arnd Dörfler, De-Hyung Lee, Ralf A Linker
BACKGROUND: Over the last decade, therapy of relapsing remitting multiple sclerosis (RRMS) has evolved with the approval of several new treatment concepts. Thus, treatment goals have become more ambitious aiming at "no evidence of disease activity" (NEDA). As NEDA-3, this concept comprises freedom of clinical disease progression and relapses as well as inflammatory MRI activity. So far, data on NEDA status mainly stem from post-hoc analyses of drug approval studies. Yet, less is known about the significance of NEDA in "real-world" clinical settings...
October 23, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/30259178/no-evidence-of-disease-activity-neda-3-and-disability-improvement-after-alemtuzumab-treatment-for-multiple-sclerosis-a-36-month-real-world-study
#8
Luca Prosperini, Pietro Annovazzi, Laura Boffa, Maria Chiara Buscarinu, Antonio Gallo, Manuela Matta, Lucia Moiola, Luigina Musu, Paola Perini, Carlo Avolio, Valeria Barcella, Assunta Bianco, Deborah Farina, Elisabetta Ferraro, Simona Pontecorvo, Franco Granella, Luigi M E Grimaldi, Alice Laroni, Giacomo Lus, Francesco Patti, Eugenio Pucci, Matteo Pasca, Paola Sarchielli
In this retrospective, multicenter, real-world study we collected clinical and magnetic resonance imaging (MRI) data of all patients (n = 40) with relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab according to a "free-of-charge" protocol available before the drug marketing approval in Italy. Almost all (39/40) started alemtuzumab after discontinuing multiple disease-modifying treatments (DMTs) because of either lack of response or safety concerns. We considered the proportion of alemtuzumab-treated patients who had no evidence of disease activity (NEDA-3) and disability improvement over a 36-month follow-up period...
December 2018: Journal of Neurology
https://www.readbyqxmd.com/read/30234431/silent-lesions-on-mri-imaging-shifting-goal-posts-for-treatment-decisions-in-multiple-sclerosis
#9
Myintzu Min, Tim Spelman, Alessandra Lugaresi, Cavit Boz, Daniele LA Spitaleri, Eugenio Pucci, Francois Grand'Maison, Franco Granella, Guillermo Izquierdo, Helmut Butzkueven, Jose Luis Sanchez-Menoyo, Michael Barnett, Marc Girard, Maria Trojano, Pierre Grammond, Pierre Duquette, Patrizia Sola, Raed Alroughani, Raymond Hupperts, Steve Vucic, Tomas Kalincik, Vincent Van Pesch, Jeannette Lechner-Scott
BACKGROUND: The current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis (MS) patients. OBJECTIVE: To evaluate the current practice of clinicians changing MS treatment based on subclinical new MRI lesions alone. METHODS: Using MSBase, an international MS patient registry with MRI data, we analysed the probability of treatment change among patients with clinically silent new MRI lesions...
October 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30217172/effect-of-interferon-beta-1a-subcutaneously-three-times-weekly-on-clinical-and-radiological-measures-and-no-evidence-of-disease-activity-status-in-patients-with-relapsing-remitting-multiple-sclerosis-at-year-1
#10
RANDOMIZED CONTROLLED TRIAL
Anthony Traboulsee, David K B Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Aaron Miller
BACKGROUND: In the PRISMS study, interferon beta-1a subcutaneously (IFN β-1a SC) reduced clinical and radiological disease burden at 2 years in patients with relapsing-remitting multiple sclerosis. The study aimed to characterize efficacy of IFN β-1a SC 44 μg and 22 μg three times weekly (tiw) at Year 1. METHODS: Exploratory endpoints included annualized relapse rate (ARR), 3-month confirmed disability progression (1-point Expanded Disability Status Scale increase if baseline was < 6...
September 14, 2018: BMC Neurology
https://www.readbyqxmd.com/read/30210582/comparable-efficacy-and-safety-of-dimethyl-fumarate-and-teriflunomide-treatment-in-relapsing-remitting-multiple-sclerosis-an-italian-real-word-multicenter-experience
#11
Emanuele D'Amico, Aurora Zanghì, Graziella Callari, Giovanna Borriello, Antonio Gallo, Giusi Graziano, Paola Valentino, Maria Buccafusca, Salvatore Cottone, Giuseppe Salemi, Paolo Ragonese, Roberto Bruno Bossio, Renato Docimo, Luigi Maria Edoardo Grimaldi, Carlo Pozzilli, Gioacchino Tedeschi, Mario Zappia, Francesco Patti
Background: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. Methods: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions)...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/30181780/peginterferon-%C3%AE-1a-every-2-weeks-increased-achievement-of-no-evidence-of-disease-activity-over-4-years-in-the-advance-and-attain-studies-in-patients-with-relapsing-remitting-multiple-sclerosis
#12
Douglas L Arnold, Shulian Shang, Qunming Dong, Matthias Meergans, Maria L Naylor
Background: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing-remitting multiple sclerosis (RRMS). Objective: To assess the NEDA status of patients treated with peginterferon β-1a in the ADVANCE and ATTAIN studies and explore its predictive value on longer-term clinical outcomes. Methods: ATTAIN was a 2-year extension of the pivotal 2-year ADVANCE study of peginterferon β-1a for RRMS...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/30160680/-issues-of-the-current-terminology-in-multiple-sclerosis
#13
A N Boyko, M R Guseva, N V Khachanova, E I Gusev
New terminology used by neurologists with multiple sclerosis (MS). The current use of terms 'definite' MS, 'MS signs', 'retrobulbar neuritis' and 'optic neuritis', 'relapse and exacerbation, types of MS course, criteria of effectiveness of MS therapy, NEDA, NEP, NEPAD; the classification therapy methods - 'escalation', 'induction' and therapy of immune reconstitution (TIR), therapy of maintenance/escalation (TME) and discussed.
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/30116299/long-term-evaluation-of-neda-3-status-in-relapsing-remitting-multiple-sclerosis-patients-after-switching-from-natalizumab-to-fingolimod
#14
Lara Diem, Krassen Nedeltchev, Timo Kahles, Lutz Achtnichts, Oliver Findling
Background: Natalizumab significantly reduces the disease activity in patients with relapsing-remitting multiple sclerosis but due to the risk of progressive multifocal leukoencephalopathy it is often discontinued. Fingolimod is seen as an alternative, but there are no long-term analyses of the efficacy of fingolimod in this setting using the no evidence of disease activity (NEDA)-3 criteria. We provide an assessment of patients who discontinued natalizumab and switched to fingolimod or other treatments by evaluating the proportion of patients who fulfil NEDA-3 criteria after prolonged follow-up periods...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/30102815/no-evidence-of-disease-activity-in-people-with-multiple-sclerosis
#15
EDITORIAL
M Marta
No abstract text is available yet for this article.
August 13, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/30090102/immunophenotype-and-transcriptome-profile-of-patients-with-multiple-sclerosis-treated-with-fingolimod-setting-up-a-model-for-prediction-of-response-in-a-2-year-translational-study
#16
Irene Moreno-Torres, Coral González-García, Marco Marconi, Aranzazu García-Grande, Luis Rodríguez-Esparragoza, Víctor Elvira, Elvira Ramil, Lucía Campos-Ruíz, Ruth García-Hernández, Fátima Al-Shahrour, Coral Fustero-Torre, Alicia Sánchez-Sanz, Antonio García-Merino, Antonio José Sánchez López
Background: Fingolimod is a functional sphingosine-1-phosphate antagonist approved for the treatment of multiple sclerosis (MS). Fingolimod affects lymphocyte subpopulations and regulates gene expression in the lymphocyte transcriptome. Translational studies are necessary to identify cellular and molecular biomarkers that might be used to predict the clinical response to the drug. In MS patients, we aimed to clarify the differential effects of fingolimod on T, B, and natural killer (NK) cell subsets and to identify differentially expressed genes in responders and non-responders (NRs) to treatment...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30021640/neurofilament-levels-disease-activity-and-brain-volume-during-follow-up-in-multiple-sclerosis
#17
Irene Håkansson, Anders Tisell, Petra Cassel, Kaj Blennow, Henrik Zetterberg, Peter Lundberg, Charlotte Dahle, Magnus Vrethem, Jan Ernerudh
BACKGROUND: There is a need for clinically useful biomarkers of disease activity in clinically isolated syndrome (CIS) and relapsing remitting MS (RRMS). The aim of this study was to assess the correlation between neurofilament light chain (NFL) in cerebrospinal fluid (CSF) and serum and the relationship between NFL and other biomarkers, subsequent disease activity, and brain volume loss in CIS and RRMS. METHODS: A panel of neurodegenerative and neuroinflammatory markers were analyzed in repeated CSF samples from 41 patients with CIS or RRMS in a prospective longitudinal cohort study and from 22 healthy controls...
July 18, 2018: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29974307/brain-volume-loss-is-present-in-japanese-multiple-sclerosis-patients-with-no-evidence-of-disease-activity
#18
Hiroaki Yokote, Tomoyuki Kamata, Shuta Toru, Nobuo Sanjo, Takanori Yokota
No evidence of disease activity-3 (NEDA-3), defined as absence of clinical relapse, disability progression, and brain magnetic resonance imaging (MRI) activity, has emerged as the therapeutic target of disease-modifying therapy for multiple sclerosis (MS). However, recent studies have revealed that NEDA-3 might not be sufficient to prevent cognitive deterioration and predict long-term disability. In addition to NEDA-3, brain atrophy has recently been recognized as a pivotal biomarker that is closely associated to disability in patients with MS...
October 2018: Neurological Sciences
https://www.readbyqxmd.com/read/29948245/two-year-real-life-efficacy-tolerability-and-safety-of-dimethyl-fumarate-in-an-italian-multicentre-study
#19
MULTICENTER STUDY
Giulia Mallucci, P Annovazzi, S Miante, V Torri-Clerici, M Matta, S La Gioia, R Cavarretta, V Mantero, G Costantini, V D'Ambrosio, M Zaffaroni, A Ghezzi, P Perini, S Rossi, A Bertolotto, M R Rottoli, M Rovaris, R Balgera, P Cavalla, C Montomoli, R Bergamaschi
BACKGROUND: Dimethyl-fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting multiple sclerosis (MS) in randomized clinical trials. OBJECTIVES: To track and evaluate post-market DMF profile in real-world setting. MATERIALS AND METHODS: Patients receiving DMF referred to Italian MS centres were enrolled and prospectively followed, collecting demographic clinical and radiological data. RESULTS: Among the 735 included patients, 45...
August 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29875218/fingolimod-vs-dimethyl-fumarate-in-multiple-sclerosis-a-real-world-propensity-score-matched-study
#20
Luca Prosperini, Matteo Lucchini, Shalom Haggiag, Paolo Bellantonio, Assunta Bianco, Maria Chiara Buscarinu, Fabio Buttari, Diego Centonze, Antonio Cortese, Laura De Giglio, Roberta Fantozzi, Elisabetta Ferraro, Arianna Fornasiero, Ada Francia, Simonetta Galgani, Claudio Gasperini, Girolama Alessandra Marfia, Enrico Millefiorini, Viviana Nociti, Simona Pontecorvo, Carlo Pozzilli, Serena Ruggieri, Marco Salvetti, Eleonora Sgarlata, Massimiliano Mirabella
OBJECTIVE: To directly compare fingolimod (FNG) and dimethyl fumarate (DMF) on no evident disease activity (NEDA) status in patients with relapsing-remitting multiple sclerosis (RRMS) from 7 multiple sclerosis outpatient clinics in Central Italy. METHODS: We analyzed data of patients with RRMS who started an oral agent, namely DMF or FNG, either as first treatment (naives) or after switching from self-injectable drugs (switchers). We performed a propensity score (PS)-based nearest-neighbor matching within a caliper of 0...
July 10, 2018: Neurology
keyword
keyword
158178
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"